<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01396512</url>
  </required_header>
  <id_info>
    <org_study_id>JEC12</org_study_id>
    <secondary_id>U1111-1117-7378</secondary_id>
    <nct_id>NCT01396512</nct_id>
  </id_info>
  <brief_title>Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers</brief_title>
  <official_title>Immunogenicity and Safety of a Single Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) in Comparison With a Single Dose of SA14-14-2 Vaccine (CD.JEVAX™, Chengdu Institute of Biological Products, China) Administered in Healthy Toddlers in South-Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Live Attenuated Japanese Encephalitis Chimeric Virus
      Vaccine (IMOJEV™) with Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine
      [CD.JEVAX™]) after a single dose vaccination to support product registration.

      Primary Objective:

        -  To demonstrate the non-inferiority of the antibody response 28 days after administration
           of one dose of IMOJEV™ compared to the antibody response 28 days after administration of
           one dose of the CD.JEVAX™ control vaccine.

      Secondary Objectives:

        -  To describe the immune response to Japanese encephalitis (JE) in both vaccine groups
           using 50% plaque reduction neutralization assay (PRNT50) assays before and after a
           single dose of IMOJEV™ vaccine or a single dose of CD.JEVAX™ vaccine.

        -  To describe the safety of vaccination in all subjects up to 28 days and all serious
           adverse events up to 6-month after vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants will receive a single dose of their assigned vaccination at Visit 1 (Day 0)
      and undergo immunogenicity assessment at Day 28 post-vaccination. Safety will be assessed
      from day of vaccination and up to 6 months post-vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion to Japanese Encephalitis Chimeric Virus Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine</measure>
    <time_frame>Day 28 post-vaccination</time_frame>
    <description>Immunogenicity assessed using a Japanese encephalitis chimeric virus (JE-CV) 50% Plaque Reduction Neutralization Test (PRNT50). Seroconversion was defined as the percentage of participants who developed neutralizing antibody titers above 10 (1/dil) when seronegative at baseline (&lt;1/10) or who presented a ≥4-fold rise in their neutralizing antibody titers when seropositive (≥1/10) at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus Before And Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 28 post-vaccination</time_frame>
    <description>Geometric mean titers were assessed using a Japanese encephalitis chimeric virus (JE-CV) 50% Plaque Reduction Neutralization Test (PRNT50).
JE-CV PRNT50 antibody titer &gt;10 (1/dil, Day 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seroprotection Against Japanese Encephalitis Chimeric Virus Before And Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 28 post-vaccination</time_frame>
    <description>Immunogenicity was assessed using a Japanese encephalitis chimeric virus (JE-CV) PRNT50 assay. Seroprotection was defined as the percentage of participants with a titer ≥10 (1/dil) at pre-vaccination and at Day 28 post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine</measure>
    <time_frame>Day 0 up to Day 14 post-vaccination</time_frame>
    <description>Solicited injection site: Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Loss, and Irritability. Grade 3 injection site: Pain - Cries when injected limb is moved or the movement of injected limb is reduced; Erythema and Swelling longest diameter ≥50 mm. Grade 3 systemic reactions: Fever &gt;39.5°C; Vomiting ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal - &gt;3 hours; Drowsiness - sleeping most of the time or difficult to wake; Appetite Loss - refuses ≥3 feeds or most feeds; Irritability - inconsolable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">274</enrollment>
  <condition>Japanese Encephalitis</condition>
  <condition>Japanese Encephalitis Virus Disease</condition>
  <arm_group>
    <arm_group_label>IMOJEV™ Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of the Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV™) on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD.JEVAX ™ Vaccine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single dose of the Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine), CD.JEVAX™ on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live attenuated Japanese encephalitis chimeric virus vaccine</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>IMOJEV™ Vaccine Group</arm_group_label>
    <other_name>IMOJEV™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>CD.JEVAX ™ Vaccine Group</arm_group_label>
    <other_name>CD.JEVAX™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 12 to 24 months on the day of inclusion

          -  In good general health, without significant medical history.

          -  Provision of informed consent form signed by at least one parent or other legally
             acceptable representative.

          -  Subject and parent/guardian able to attend all scheduled visits and comply with all
             trial procedures.

        Exclusion Criteria:

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding the trial vaccination.

          -  Planned participation in another clinical trial during the present trial period.

          -  Known or suspected congenital or acquired immunodeficiency, or receipt of
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within
             the preceding 6 months, or long-term systemic corticosteroids therapy.

          -  Known systemic hypersensitivity to any of IMOJEV™ components or history of a
             life-threatening reaction to a vaccine containing any of the same substances and
             vaccination,known systemic hypersensitivity to CD.JEVAX® main components and the other
             components (including Gelatin, kanamycin, and gentamicin).

          -  Chronic illness at a stage that could interfere with trial conduct or completion, in
             the opinion of the Investigator.

          -  Receipt of blood or blood-derived products in the past 3 months, that might interfere
             with the assessment of the immune response.

          -  Previous vaccination against flavivirus disease, including Japanese encephalitis (JE).

          -  Administration of any anti-viral within 2 months preceding Visit 01 and up to the 4
             weeks following the trial vaccination.

          -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except
             for pandemic influenza vaccination, which may be received at least two weeks before
             the study vaccines.

          -  Planned receipt of any vaccine from the inclusion up to the 4 weeks following the
             trial vaccination.

          -  History of central nervous system disorder or disease, including seizures.

          -  Planned receipt of any JE vaccine during the course of the study.

          -  History of flavivirus infection (confirmed either clinically, serologically or
             virologically).

          -  Administration of systemic corticosteroids for more than two consecutive weeks within
             the 4 weeks preceding vaccination.

          -  Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection 3
             days before vaccination as well as the day of vaccination, according to Investigator
             judgment.

          -  Thrombocytopenia or bleeding disorder contraindicated for vaccination with same
             administration route, or receipt of anticoagulants in the 3 weeks preceding inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2011</study_first_submitted>
  <study_first_submitted_qc>July 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2011</study_first_posted>
  <results_first_submitted>March 24, 2014</results_first_submitted>
  <results_first_submitted_qc>March 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2014</results_first_posted>
  <last_update_submitted>March 24, 2014</last_update_submitted>
  <last_update_submitted_qc>March 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese Encephalitis</keyword>
  <keyword>Japanese Encephalitis Virus Disease</keyword>
  <keyword>IMOJEV™</keyword>
  <keyword>CD.JEVAX™</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study participants were enrolled from 12 July 2011 to 28 September 2012 at 10 clinic centers in South Korea.</recruitment_details>
      <pre_assignment_details>A total of 274 participants who met all of the inclusion and none of the exclusion criteria were randomized and vaccinated in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IMOJEV™ Vaccine Group</title>
          <description>Participants age 12 to 24 months received one dose of IMOJEV™</description>
        </group>
        <group group_id="P2">
          <title>CD.JEVAX™ Vaccine Group</title>
          <description>Participants age 12 to 24 months received one dose of CD.JEVAX™</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IMOJEV™ Vaccine Group</title>
          <description>Participants age 12 to 24 months received one dose of IMOJEV™</description>
        </group>
        <group group_id="B2">
          <title>CD.JEVAX™ Vaccine Group</title>
          <description>Participants age 12 to 24 months received one dose of CD.JEVAX™</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="137"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="274"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.0" spread="2.0"/>
                    <measurement group_id="B2" value="14.3" spread="2.2"/>
                    <measurement group_id="B3" value="14.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion to Japanese Encephalitis Chimeric Virus Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine</title>
        <description>Immunogenicity assessed using a Japanese encephalitis chimeric virus (JE-CV) 50% Plaque Reduction Neutralization Test (PRNT50). Seroconversion was defined as the percentage of participants who developed neutralizing antibody titers above 10 (1/dil) when seronegative at baseline (&lt;1/10) or who presented a ≥4-fold rise in their neutralizing antibody titers when seropositive (≥1/10) at baseline.</description>
        <time_frame>Day 28 post-vaccination</time_frame>
        <population>Seroconversion to JE-CV was assessed in the Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>IMOJEV™ Vaccine Group</title>
            <description>Participants age 12 to 24 months received one dose of IMOJEV™</description>
          </group>
          <group group_id="O2">
            <title>CD.JEVAX™ Vaccine Group</title>
            <description>Participants age 12 to 24 months received one dose of CD.JEVAX™</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to Japanese Encephalitis Chimeric Virus Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine</title>
          <description>Immunogenicity assessed using a Japanese encephalitis chimeric virus (JE-CV) 50% Plaque Reduction Neutralization Test (PRNT50). Seroconversion was defined as the percentage of participants who developed neutralizing antibody titers above 10 (1/dil) when seronegative at baseline (&lt;1/10) or who presented a ≥4-fold rise in their neutralizing antibody titers when seropositive (≥1/10) at baseline.</description>
          <population>Seroconversion to JE-CV was assessed in the Per-Protocol Analysis Set.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus Before And Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine</title>
        <description>Geometric mean titers were assessed using a Japanese encephalitis chimeric virus (JE-CV) 50% Plaque Reduction Neutralization Test (PRNT50).
JE-CV PRNT50 antibody titer &gt;10 (1/dil, Day 0)</description>
        <time_frame>Day 0 (pre-vaccination) and Day 28 post-vaccination</time_frame>
        <population>Geometric mean titers against the JE-CV was assessed in the Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>IMOJEV™ Vaccine Group</title>
            <description>Participants age 12 to 24 months received one dose of IMOJEV™</description>
          </group>
          <group group_id="O2">
            <title>CD.JEVAX™ Vaccine Group</title>
            <description>Participants age 12 to 24 months received one dose of CD.JEVAX™</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus Before And Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine</title>
          <description>Geometric mean titers were assessed using a Japanese encephalitis chimeric virus (JE-CV) 50% Plaque Reduction Neutralization Test (PRNT50).
JE-CV PRNT50 antibody titer &gt;10 (1/dil, Day 0)</description>
          <population>Geometric mean titers against the JE-CV was assessed in the Per-Protocol Analysis Set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JE-CV PRNT50 antibody titer (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE-CV PRNT50 antibody titer (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="908" lower_limit="656" upper_limit="1256"/>
                    <measurement group_id="O2" value="579" lower_limit="427" upper_limit="784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seroprotection Against Japanese Encephalitis Chimeric Virus Before And Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine</title>
        <description>Immunogenicity was assessed using a Japanese encephalitis chimeric virus (JE-CV) PRNT50 assay. Seroprotection was defined as the percentage of participants with a titer ≥10 (1/dil) at pre-vaccination and at Day 28 post-vaccination.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 28 post-vaccination</time_frame>
        <population>Seroprotection against JE-CV was assessed in the Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>IMOJEV™ Vaccine Group</title>
            <description>Participants age 12 to 24 months received one dose of IMOJEV™</description>
          </group>
          <group group_id="O2">
            <title>CD.JEVAX™ Vaccine Group</title>
            <description>Participants age 12 to 24 months received one dose of CD.JEVAX™</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroprotection Against Japanese Encephalitis Chimeric Virus Before And Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine</title>
          <description>Immunogenicity was assessed using a Japanese encephalitis chimeric virus (JE-CV) PRNT50 assay. Seroprotection was defined as the percentage of participants with a titer ≥10 (1/dil) at pre-vaccination and at Day 28 post-vaccination.</description>
          <population>Seroprotection against JE-CV was assessed in the Per-Protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JE-CV PRNT50 antibody titer ≥10 (1/dil, Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE-CV PRNT50 antibody titer ≥10 (1/dil, Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="116" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine</title>
        <description>Solicited injection site: Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Loss, and Irritability. Grade 3 injection site: Pain - Cries when injected limb is moved or the movement of injected limb is reduced; Erythema and Swelling longest diameter ≥50 mm. Grade 3 systemic reactions: Fever &gt;39.5°C; Vomiting ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal - &gt;3 hours; Drowsiness - sleeping most of the time or difficult to wake; Appetite Loss - refuses ≥3 feeds or most feeds; Irritability - inconsolable.</description>
        <time_frame>Day 0 up to Day 14 post-vaccination</time_frame>
        <population>Solicited injection site reactions and systemic reactions were assessed in the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>IMOJEV™ Vaccine Group</title>
            <description>Participants age 12 to 24 months received one dose of IMOJEV™</description>
          </group>
          <group group_id="O2">
            <title>CD.JEVAX™ Vaccine Group</title>
            <description>Participants age 12 to 24 months received one dose of CD.JEVAX™</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine</title>
          <description>Solicited injection site: Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Loss, and Irritability. Grade 3 injection site: Pain - Cries when injected limb is moved or the movement of injected limb is reduced; Erythema and Swelling longest diameter ≥50 mm. Grade 3 systemic reactions: Fever &gt;39.5°C; Vomiting ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal - &gt;3 hours; Drowsiness - sleeping most of the time or difficult to wake; Appetite Loss - refuses ≥3 feeds or most feeds; Irritability - inconsolable.</description>
          <population>Solicited injection site reactions and systemic reactions were assessed in the Safety Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="38" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Pain (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="33" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Erythema (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Swelling (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N = 134, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="34" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (N = 134, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying Abnormal (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="35" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying Abnormal (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="33" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Loss (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="40" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite Loss (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="36" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (N = 137, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from Day 0 (post-vaccination) up to Day 28 post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IMOJEV™ Vaccine Group</title>
          <description>Participants age 12 to 24 months received one dose of IMOJEV™</description>
        </group>
        <group group_id="E2">
          <title>CD.JEVAX™ Vaccine Group</title>
          <description>Participants age 12 to 24 months received one dose of CD.JEVAX™</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hand foot and mouth disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lymph node abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Injection site Pain</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="137"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Injection site Erythema</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="137"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Injection site Swelling</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="134"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="54" subjects_affected="42" subjects_at_risk="137"/>
                <counts group_id="E2" events="44" subjects_affected="38" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite Loss</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="137"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="137"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying Abnormal</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="137"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="137"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

